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During 45 years, the Instituto Clodomiro Picado (ICP, University of Costa Rica) has developed an ambi-
tious scientiﬁc, technological, productive, and social program aimed at providing a better understanding
of snakes and their venoms, contributing to the development, production and distribution of antivenoms,
improving the prevention and management of snakebite envenomings, and strengthening human re-
sources in science and technology. Among other topics, its research agenda has focused on the local
tissue alterations induced by viperid snake venoms, i.e. myonecrosis, hemorrhage, dermonecrosis,
extracellular matrix degradation, lymphatic vessel damage, and inﬂammation. In addition, the preclinical
efﬁcacy of antivenoms has been thoroughly investigated, together with the technological development of
novel antivenoms. ICP's project has been based on a philosophical frame characterized by: (a) An inte-
grated approach for confronting the problem of snakebites, involving research, production, extension
activities, and teaching; (b) a cooperative and team work perspective in the pursuit of scientiﬁc, tech-
nological, productive, and social goals; (c) a search for excellence and continuous improvement in the
quality of its activities; and (d) a vision of solidarity and compassion, based on the realization that
snakebite envenomings mostly affect impoverished vulnerable populations in the rural settings of
developing countries. A key aspect in this program has been the consolidation of international part-
nerships with groups of all continents, within a frame of academic and social cooperation, some of which
are described in this review.
© 2015 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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The scientiﬁc study of venomous snakes and their venoms in
Costa Rica started with the pioneering work of Clodomiro Picado
Twight (1887e1944), during the ﬁrst decades of the 20th century
(Fig. 1). Picado, a talented person interested in natural history, was
awarded a scholarship to perform advanced studies at La Sorbonne,
from 1908 to 1913. During his last year in France, he also received
training inMedical Microbiology at Institut Pasteur. Upon his return
to Costa Rica, Picado was appointed Director of the Clinical Labo-
ratory of Hospital San Juan de Dios, at that time the main health
center in the country. In addition to introducing modern methods
for laboratory diagnosis, which represented a leap forward in the
medical practice in the country, he established an ambitious
research program which covered a wide array of topics, including
Medical Microbiology, Immunology, Experimental Pathophysi-
ology, Clinical Chemistry, Hematology, Therapeutics, Phytopa-
thology, and General Biology (Gutierrez, 1986).
One of the subjects that captured the attention of Picadowas the
problem of snakebite envenoming, which was then, as it is now, a
serious public health hazard in the country. Taking an integrated
approach to the subject, he developed a serpentarium at the hos-
pital, collected venoms, and studied a variety of aspects including
the biology of snakes, the toxicology of venoms, and the therapy of
envenomings. His contributions in the ﬁeld of Toxinology areFig. 1. Pioneers of Toxinology in Costa Rica. Left, Clodomiro Picado Twight (1887e1944). Afte
Laboratory of Hospital San Juan de Dios (San Jose, Costa Rica). In addition to his work on diag
among other topics, the study of snakes, snake venoms, and snakebite envenomings. Ri
Microbiology (University of Costa Rica). In the decade of 1960 he was involved in an inter-in
of this project, the Instituto Clodomiro Picado was created in 1970, and Bola~nos was its Dir
promoted an innovative integrated approach for confronting snakebite envenomings, involvi
170e171, Gutierrez, Bothrops asper: Beauty and peril in the Neotropics, copyright 2009,
permission from Elsevier.summarized in the book Serpientes Venenosas de Costa Rica. Sus
Venenos. Seroterapia Antiofídica (Picado, 1931). It may be said that
Picado introduced in Costa Rica what is currently known as
‘translational research’, since he went from the laboratory studies
to the implementation of practical solutions to the problem. Being
aware of the developments that had taken place since 1901 in
Brazil, associated with the production of the ﬁrst antivenoms in
Latin America, at Instituto Butantan, under the leadership of Vital
Brazil Mineiro da Campanha (Brazil, 1911), Picado hypothesized
that the similarities between the venoms of Brazilian and Costa
Rican viperid snakes could imply that antivenoms manufactured in
Brazil would be effective in Costa Rica. Through an agreement with
Instituto Butantan, Brazilian antivenoms were imported to Costa
Rica, and used in the treatment of patients. The success of this
approach initiated the modern era of snakebite envenoming ther-
apy in Central America (Picado, 1931).
In addition to scientiﬁc research and the introduction of anti-
venoms, Picado also worked in the political front, promoting, in
association with the Minister of Health of Costa Rica, Solon Nú~nez
Frutos, a unique and highly progressive legislation that, among
other issues, implemented the use of antivenoms in the country,
the access of this therapy in rural settings, and the obligation of
land owners to keep a stock of antivenom in case their workers
suffered a snakebite (Picado, 1931; Gutierrez, 2010).
The legacy of Clodomiro Picado germinated in the 1960s as anr completing advanced studies in France, Picado was appointed Director of the Clinical
nostic laboratory aspects, he developed an ambitious research programwhich included,
ght, Roger Bola~nos Herrera (1931e2007), professor of Immunology at the School of
stitutional program aimed at producing antivenoms in Costa Rica. Owing to the success
ector from 1970 to 1980. He performed studies on snake venoms and antivenoms, and
ng research, antivenom production, teaching and extension. Reprinted from Toxicon 50:
and Toxicon 54: 901e903, Gutierrez, Obituary: Roger Bola~nos, copyright 2007, with
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Antiofídicos (Program for Antivenoms). This effort, jointly promoted
by the Ministry of Health, the University of Costa Rica and the
Embassy of the United States of America in Costa Rica, was aimed at
initiating the local production of antivenoms (Gutierrez, 2010). It
was developed in the context of a profound transformation of the
public health institutions in Costa Rica, as part of the social-
democratic project that dominated the political landscape of the
country in those years (Jaramillo, 1993). Under the leadership of
Roger Bola~nos (1931e2007) (Fig. 1) and Herschel H. Flowers, the
program succeeded in producing the ﬁrst batches of polyvalent and
anticoral antivenoms in 1967 (see Gutierrez (2010) for a detailed
account of the origins and goals of the project).
The success of this initiative led to the creation of Instituto
Clodomiro Picado (ICP), in 1970, as the institution responsible for
the manufacture of antivenoms for the country, with Roger Bola~nos
appointed as its ﬁrst Director. Bola~nos, a professor of Immunology
at the School of Microbiology of the University of Costa Rica, pro-
moted an integrated approach to the issue of snakebite envenom-
ing, one that inherited and expanded the philosophy implemented
by Clodomiro Picado Twight (Gutierrez, 2007, 2010). In 1972,
through an agreement between the Ministry of Health and the
University of Costa Rica, the administration of ICP was transferred
to this university; this event has had signiﬁcant implications for the
strengthening of Toxinology and of antivenom production in the
country.
2. The philosophical basis of an ambitious project
Roger Bola~nos and his colleagues at ICP had a vision on how to
study and confront snakebite envenoming which, since then, has
been the philosophical basis for the development of ICP. This phi-
losophy, which ﬁts within the main goals of the University of Costa
Rica, is based on four main pillars:
(a) The view that, for an effective approach to this complex
public health problem, an integrated perspective had to be
implemented, including (i) scientiﬁc and technological
research on snakes, venoms and antivenoms; (ii) develop-
ment, production and distribution of antivenoms; (iii)
strengthening of human resources through graduate and
undergraduate teaching programs at the university; and (iv)
extension programs to convey the basic knowledge of pre-
vention and management of snakebite envenomings to
communities, vulnerable social groups, and health
professionals.
(b) A permanent search for excellence in all aspects of ICP's ac-
tivities, getting away from comfort zones, and searching for
new scientiﬁc, technological, productive and social
challenges.
(c) The promotion of a cooperative and team work approach in
the fulﬁllment of objectives. The confrontation of the difﬁcult
tasks that ICP had to undertake was possible only through a
collective agenda, characterized by a continued coordination
between the various sections and workers. This cooperative
perspectivewas implemented not only within ICP, but also in
the collaborations that this institute has established with
other groups in many countries along the years.
(d) A philosophy of solidarity and compassion, based on the fact
that snakebite envenomings cause much suffering among
vulnerable human groups living in impoverished rural set-
tings. Thus, in the long term, the efforts carried out on
various fronts by ICP have had the aim of reducing such
suffering, through science, technology, and social
entrepreneurship.3. Scientiﬁc research at ICP: towards understanding the
complex landscape of local tissue damage induced by viperid
snake venoms
One of the most drastic consequences of viperid snakebite
envenomings is the development of local pathological effects,
characterized by edema, myonecrosis, dermonecrosis, blistering,
and hemorrhage (Warrell, 2004; Cardoso et al., 2009). If not treated
promptly and effectively, this may result in permanent tissue
damage and sequelae, with long lasting physical and psychological
effects in affected people. This subject has been of interest to re-
searchers at ICP since the early years of the decade of 1980. After a
general characterization of myotoxic and hemorrhagic activities of
Costa Rican viperid venoms (Gutierrez and Chaves, 1980), various
research projects have contributed to understanding the
complexity of these phenomena.
3.1. Myonecrosis
When describing the myotoxic activity induced by the venom of
Bothrops asper, the most important venomous snake of Central
America, it was proposed that the quantiﬁcation of the plasma
levels of the enzyme creatine kinase (CK) could be used as a marker
to assess the extent of myonecrosis (Gutierrez et al., 1980). The
isolation of a myotoxic phospholipase A2 (PLA2), and the study of its
mechanism of action, was performed in collaboration with Char-
lotte L. Ownby, the author's PhD supervisor, at Oklahoma State
University (USA). It was proposed that this myotoxin induces acute
muscle damage by ﬁrst affecting the integrity of skeletal muscle
plasma membrane, through phospholipid hydrolysis, thus pro-
moting a prominent calcium inﬂux which sets the stage for a series
of intracellular degenerative events that lead to irreversible cell
damage (Gutierrez et al., 1984a, b).
Further studies in Costa Rica led to the isolation of several new
myotoxins from various snake venoms (see Lomonte and Rangel
(2012) for a review). Surprisingly, some of these myotoxins had
PLA2 structure, but were devoid of catalytic activity (Lomonte and
Gutierrez, 1989). Through a collaboration with the group of Ivan I.
Kaiser, at the University ofWyoming (USA), it was found that one of
these toxins, B. asper myotoxin II, is a Lys49 PLA2 homologue, pre-
senting modiﬁcations not only at position 49 but also in some
residues of the so called ‘calcium-binding loop’ (Francis et al., 1991).
This myotoxin has become a useful tool to investigate the mecha-
nisms involved in skeletal muscle damage in the absence of phos-
pholipid hydrolysis. Working with this toxin at the laboratory of
Lars Å. Hanson, at the University of G€oteborg (Sweden), Bruno
Lomonte identiﬁed a stretch of hydrophobic and cationic residues
in the C-terminal region of myotoxin II which was responsible for
membrane damage (Lomonte et al., 1994a). Later on, the 3D
structure of this myotoxin was described in collaboration with
Rhaguvir R. Arni, of Universidade Estadual Paulista (Brazil) (Arni
et al., 1995). The ability of catalytically-active and inactive myo-
toxins to disrupt bilayers was then explored using liposomes as
models; it was observed that liposomes made of negatively-
charged phospholipids were more susceptible to the action of
these toxins (Díaz et al., 1991; Ruﬁni et al., 1992).
The use of myoblast/myotube cell cultures for assessing the
cytotoxic activity of snake venommyotoxins has been instrumental
for deciphering various aspects of their mechanism of action
(Lomonte et al., 1999), such as the role of toxin dimerization in the
ability to induce cytotoxicity (Angulo et al., 2005), the effect of
cholesterol and membrane ﬂuidity in the susceptibility of myo-
blasts (Rangel et al., 2011), and the synergistic action of Asp49-and
Lys49 PLA2s (Mora-Obando et al., 2014). On the other hand, when
exploring myotoxicity induced by elapid venom PLA2s, and in
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J€ornvall, at Karolinska Institutet (Sweden), Alberto Alape-Giron
proposed a hypothesis describing the evolutionary steps in the
acquisition of myotoxicity in these PLA2s, and identiﬁed key resi-
dues in these PLA2s necessary to exert acute muscle damage
(Alape-Giron et al., 1999).
More recently, through a collaboration with the group of Cesare
Montecucco, at the University of Padova (Italy), new insights have
been gained on the mechanism of action of viperid myotoxic PLA2s.
Using a mass spectrometric approach to quantify phospholipids
and lysophospholipids in muscle tissue and myotubes in culture, it
was found that a catalytically-active myotoxic PLA2 induced pre-
dominantly hydrolysis of phosphatidylcholine, whereas a
catalytically-inactive PLA2 homologue did not, thus demonstrating
that intracellular PLA2s do not seem to play a key role in membrane
damage in this model (Fernandez et al., 2013). Moreover, using
single cell ﬂuorescent measurement with Fura-2, it was found that
both types of myotoxins induced a rapid increment in cytosolic
calcium, which was largely abrogated by eliminating extracellular
calcium (Cintra-Francischinelli et al., 2009). A possible adaptive role
for having catalytically-active and -inactive myotoxic PLA2s in a
single venom was inferred from studies showing a synergism be-
tween these two types of myotoxins in promoting damage to
muscle cell plasma membrane (Mora-Obando et al., 2014).
On the basis of these experimental observations, a uniﬁed view
of the mechanism of action of these myotoxins has been proposed
(Gutierrez and Ownby, 2003; Montecucco et al., 2008; Lomonte
and Rangel, 2012) (Fig. 2). Myotoxic PLA2s and PLA2 homologuesMyotoxic PLA2s and PL
Binding to ‘acceptors’ in plasma me
disruption by catalytically-dependen
Loss of control of 
Depolarization Ca2+ influx Loss of ionic gradien
Hypercontraction
Mechanical damage
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Dis
Hydrolysis of key structural
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Fig. 2. Proposed sequence of cellular events occurring as a consequence of the action of
Myotoxins bind to as yet unidentiﬁed ‘acceptor’ sites at the plasma membrane, inducing a r
the case of Asp49 PLA2s) and catalyticallyeindependent (in the case of Lys49 PLA2 homologu
and macromolecules. The main consequence of this alteration is a prominent Ca2þ inﬂu
hypercontraction, mitochondrial alterations, and activation of cytosolic Ca2þ-dependent p
irreversible damaged. Reprinted, with slight modiﬁcations, from Toxicon 42: 915e931, Guti
Insights into the mechanisms of local and systemic myotoxicity, copyright 2003, with perminteract with as yet unidentiﬁed ‘acceptors’ in skeletal muscle cell
plasma membrane, provoking rapid membrane disruption by
catalytically-dependent and independent mechanisms. The main
consequence of this membrane perturbation is a rapid inﬂux of
extracellular calcium which, in turn, results in: (a) Hyper-
contraction of myoﬁlaments, (b) calcium uptake by mitochondria,
eventually resulting in calcium overload and mitochondrial dam-
age, and (c) activation of calcium-dependent intracellular pro-
teinases (calpains) and probably PLA2s.
3.2. Hemorrhage
Local and systemic bleeding are two frequent and serious
manifestations of viperid snakebite envenomings (Warrell, 2004;
Cardoso et al., 2009). The ability of these venoms to induce hem-
orrhage depends on the action of zinc-dependent metal-
loproteinases (SVMPs) on the microvasculature (Fox and Serrano,
2005; Gutierrez et al., 2005a). The characterization of hemorrhag-
ic SVMPs from the venom of B. asper was undertaken in a collab-
orative project between ICP and Michael Ovadia and Gadi Borkow,
from the University of Tel Aviv (Israel) (Borkow et al., 1993;
Gutierrez et al., 1995). A P-I SVMP isolated from this venom,
named BaP1, has become a useful tool for investigating the mech-
anism of microvessel damage and hemorrhage (Gutierrez et al.,
1995; Watanabe et al., 2003). Its primary and tertiary structures
were described through collaborations with Raghuvir Arni (Uni-
versidade Estadual Paulista, Brazil) and Jay W. Fox (University of
Virginia, USA), and later on with Torsten Lingott and IrmgardA2 homologues
mbrane followed by membrane
t or –independent mechanisms
permeability
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molecules
Internalization of 
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myotoxic PLA2s and PLA2 homologues from viperid venoms in skeletal muscle cells.
apid and drastic membrane perturbation which is based on catalytically-dependent (in
es) events. Membrane damage results in the loss of the control of permeability to ions
x which triggers a series of intracellular degenerative events, such as myoﬁlament
roteinases and PLA2s. Muscle cells rapidly pass the ‘point of no return’ and become
errez and Ownby, Skeletal muscle degeneration induced by venom phospholipases A2:
ission from Elsevier.
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Lingott et al., 2009).
The mechanism of action of hemorrhagic SVMPs has been
explored in depth at ICP, using a variety of experimental approaches
that include light and electron microscopy, intravital microscopy,
immunohistochemistry, endothelial cell cultures, Western blot
analysis, and proteomic characterization of exudates collected in
the vicinity of damaged tissue. Light and electron microscopic ob-
servations revealed a rapid disruption of capillary vessel structure
after injection of SVMPs, characterized by a drop in the number of
pinocytotic vesicles and a reduction in the width of endothelial
cells, associated with a distention and eventual disruption of
capillary wall (Moreira et al., 1994; Rucavado et al., 1995). Inter-
estingly, SVMPs do not induce direct damage of endothelial cells in
culture, but instead provoke the detachment of these cells, which
eventually die by apoptosis (Lomonte et al., 1994b; Rucavado et al.,
1995; Díaz et al., 2005).
The action of SVMPs on the basement membrane (BM) sur-
rounding endothelial cells in capillaries has been investigated by
Teresa Escalante, Alexandra Rucavado, Cristina Herrera, and the
author, in collaboration with the groups of Jay W. Fox (University
of Virginia, USA), Sussan Nourshargh and Mathieu-Benoit Voisin
(Queen Mary University of London, UK), and Eladio F. Sanchez
(Fundaçao Ezequiel Dias, Brazil). By a combination of an in vitro
model, based on hydrolysis of Matrigel, a BM preparation from a
sarcoma cell line, and in vivo and ex vivo assessment of BM hy-
drolysis, based on Western blotting and immunohistochemistry
analyses, it was found that SVMPs are able to degrade laminin,
type IV collagen, nidogen, and heparan sulphate proteoglycan
(Escalante et al., 2006, 2011a; Herrera et al., 2015). When
comparing the action of P-I hemorrhagic and non-hemorrhagic
SVMPs, a striking difference was noticed regarding theFig. 3. Proposed ‘two-step’ mechanism of action of snake venom hemorrhagic zinc-depe
components of the basement membrane (BM) that surrounds endothelial cells in capillary bl
due to the presence of exosites in the disintegrin-like and cysteine-rich domains, which ena
activity of hemorrhagic SVMPs is likely to be type IV collagen, since it plays a key role in the
proteolysis of BM components, the capillary wall becomes weakened, and the action of hem
shear stress, provokes the distention of endothelial cell and, eventually, the disruption in t
Proteomics 74: 1781e1794, Escalante et al., Key events in microvascular damage induced by
Elsevier.hydrolysis of type IV collagen (Escalante et al., 2011a). It was thus
suggested that enzymatic degradation of this BM component is a
key step in the pathogenesis of hemorrhage, owing to the prom-
inent role that this collagen plays in the mechanical stability of BM
and the capillary wall. This hypothesis has been recently sup-
ported by further observations with hemorrhagic P-I, P-II, and P-III
SVMPs (Herrera et al., 2015).
These studies have been complemented by a new approach to
assess venom-induced tissue damage, based on the proteomic
characterization of exudates collected in the vicinity of tissues
injected with venoms or isolated toxins. These analyses, performed
in collaborationwith JayW. Fox, provide a ‘window’ through which
more subtle aspects of tissue damage can be explored (Escalante
et al., 2009, 2011a; Rucavado et al., 2011). In particular, fragments
of several extracellular matrix (ECM) proteins have been detected,
thus revealing hitherto unknown aspects of SVMP action in the
tissues.
Taken together, these experimental ﬁndings on the mechanism
of action of hemorrhagic SVMPs have been uniﬁed in a ‘two-step
model’ (Fig. 3). Initially, hemorrhagic SVMPs bind and hydrolyze
components in the BM of capillary vessels, the degradation of type
IV collagen being of particular relevance. P-II and P-III SVMPs bind
more speciﬁcally to capillary BM than P-I SVMP, owing to the
presence of exosites in the disintegrin, disintegrin-like and
cysteine-rich domains of these SVMPs (Baldo et al., 2010; Herrera
et al., 2015), thus explaining their generally higher hemorrhagic
activity. BM degradation results in the weakening of the mechan-
ical stability of the capillary wall; as a consequence, the hemody-
namic forces normally operating in the vasculature in vivo, i.e.
hydrostatic pressure and shear stress, provoke the distention and
the eventual disruption of the capillary wall, leading to extravasa-
tion (Gutierrez et al., 2005a; Escalante et al., 2011b).ndent metalloproteinases (SVMPs) in capillary blood vessels. SVMPs hydrolyze key
ood vessels. P-III SVMPs in general have a higher hemorrhagic potential than P-I SVMPs
ble them to bind to targets in the BM. The most important substrate for the proteolytic
mechanical stability of the BM and hence of the capillary wall. After this ﬁrst step, i.e.
odynamic biophysical forces operating in the circulation, i.e. hydrostatic pressure and
he integrity of the capillary wall, resulting in extravasation. Reprinted from Journal of
snake venom hemorrhagic metalloproteinases, copyright 2011, with permission from
J.M. Gutierrez / Toxicon 109 (2016) 51e62563.3. Damage to skin and to lymphatic vessels
Two additional aspects of viperid venom-induced local pathol-
ogy that have been investigated at ICP are the effects on skin and
lymphatic vesicles. SVMPs induce blistering and dermonecrosis, as
a consequence of the degradation of proteins of the der-
maleepidermal junction (Jimenez et al., 2008; Escalante et al.,
2009). On the other hand, B. asper venom and a Lys49 PLA2 ho-
mologue from this venom induce a reduction in the lumen of col-
lecting lymphatic vessels in the mesentery, followed by the halting
of lymph ﬂow (Mora et al., 2008). This effect is secondary to the
action of this myotoxin on smooth muscle cells of the lymphatic
vessel wall.
3.4. Exploring the causes of deﬁcient skeletal muscle regeneration
after venom-induced myonecrosis
Clinical observations indicate that regeneration of skeletal
muscle after myonecrosis in viperid snakebite envenoming is often
deﬁcient, thus resulting in permanent tissue loss and disability. A
successful muscle regenerative process depends on a number of
factors, namely the removal of necrotic material, the presence of
intact blood supply and innervation, and the permanence of the BM
surrounding necrotic ﬁbers, which serves a scaffolding role in the
regenerative process (Ciciliot and Schiafﬁno, 2010). These re-
quirements are largely hampered in muscle tissue affected by
viperid snake venoms. In the case of the venom of B. asper, our
studies in collaborationwith Alexandra Rucavado (ICP) and Rosario
Hernandez and Patricia Saravia-Otten (Universidad de San Carlos,
Guatemala) have shown that the density of microvessels and of
axons within intramuscular nerves is greatly reduced, as a conse-
quence of the action of tissue-damaging toxins (Gutierrez et al.,
1984c; Arce et al., 1991; Hernandez et al., 2011). The observation
of TUNEL-positive regenerative cells strongly supports the view
that the tissue microenvironment does not provide the conditions
necessary for regeneration (Hernandez et al., 2011). Through a
collaboration with Stefano Gastaldello (Karolinska Institutet, Swe-
den) and Patricia Saravia-Otten, it was found that homogenates of
muscle tissue collected several days after injection of B. asper
venom and toxins inhibit myoblast cell proliferation and fusion into
myotubes in a cell culture model (Saravia-Otten et al., 2013). It is
expected that a more thorough understanding of the basis of this
poor regenerative process may lead the way to therapeutic in-
terventions aimed at improving this outcome.
3.5. Inﬂammation in venom-affected tissues
The action of viperid snake venoms in the tissues is associated
with a complex inﬂammatory reaction, characterized by edema,
pain, and inﬂammatory cell inﬁltrate. Inﬂammation induced by the
venom of B. asper and by puriﬁed SVMPs and myotoxic PLA2s and
PLA2 homologues has been investigated through collaborations
between ICP and the groups of Catarina F.P. Teixeira and Yara Cury
(Instituto Butantan, Brazil) (see reviews by Teixeira et al., 2003a,
2009). Edema and pain occur as a consequence of the activation
of several inﬂammatory pathways, with the release of histamine,
and the generation of prostaglandins, leukotrienes, kinins, nitric
oxide, complement anaphylatoxins, and cytokines, together with
the synthesis of proteinases, mostly matrix metalloproteinases
(MMPs) (Rucavado et al., 2002; Teixeira et al., 2009). These and
other mediators act on venular endothelial cells and on a variety of
nociceptors in afferent neurons, provoking edema and pain. PLA2s
and SVMPs also act directly on resident macrophages and other
inﬂammatory cells, inducing their activation (Zamuner et al., 2001;
Zuliani et al., 2005; Leiguez et al., 2011).Whether inﬂammation contributes to further tissue damage in
muscle injected with the venom of B. asper is an open question that
has been explored by Fernando Chaves and colleagues at ICP, and by
researchers at Instituto Butantan (Teixeira et al., 2003b; Chaves
et al., 2005, 2006). Other studies have focused on the possible
role in venom-induced pathology of tissue components, i.e. danger
signals or DAMPs, released as a consequence of myonecrosis and
ECM degradation. For example, the release of ATP from damaged
muscle cells results in the expansion of myocyte damage through
the action of this nucleotide on purinergic receptors, resulting in
the increment of cytosolic calcium and the consequent cytotoxicity
(Cintra-Francischinelli et al., 2010).
The large body of experimental observations gathered over the
years in the study of venom-induced local tissue damage by re-
searchers of ICP and other groups is summarized in Fig. 4. There is a
direct toxic action of venom components, mostly SVMPs, PLA2s and
PLA2 homologues. These early pathological events, in turn, generate
an inﬂammatory reaction, in association with the direct effect of
venom components on resident and inﬂammatory cells. The
myriad of inﬂammatory mediators released in the tissue set the
onset of reparative and regenerative events, but might also
contribute to further tissue damage and to impaired regeneration.
A more deep understanding of this complex scenario is necessary
for the design of knowledge-based therapeutic interventions aimed
at ameliorating the magnitude of tissue damage and at improving
the regenerative outcome. These are urgent challenges that de-
mand renewed collaborative research efforts.
4. Towards a better characterization of the preclincal efﬁcacy
of antivenoms
The traditional way to evaluate the capacity of antivenoms to
neutralize snake venoms is based on the lethality neutralization
test, which is the gold standard for assessing antivenom potency
(WHO, 2010; Gutierrez et al., 2013). This test involves the incuba-
tion of a ﬁxed dose of venom with various dilutions of antivenom,
using a control group in which venom is incubated with saline
solution instead of antivenom. After an incubation interval, aliquots
of the mixtures, containing a ‘challenge dose’ of venom (usually
either 3, 4 or 5Median Lethal Doses, LD50s) are injected inmice, and
lethality is observed. Antivenom efﬁcacy is thus expressed as the
Median Effective Dose (ED50), i.e. the ratio venom/antivenom at
which half of the injected animals survive (WHO, 2010; Gutierrez
et al., 2013). Using this experimental approach, Bola~nos demon-
strated that the polyvalent (viperid) antivenom manufactured at
Instituto Clodomiro Picado (ICP) is effective in the neutralization of
lethality of Costa Rican venoms of snakes from the family Viperidae
(Bola~nos, 1971).
Following early developments, especially by David Theakston
and colleagues, at the Liverpool School of Tropical Medicine (UK)
(Theakston and Reid, 1983), and by researchers at ICP, a new
rationale of the assessment of the preclinical efﬁcacy of antivenoms
was developed. Since viperid, and some elapid, venoms induce a
variety of pathologically- and pathophysiologically-relevant effects,
in addition to lethality, it was considered that a more thorough
characterization of antivenoms' preclinical efﬁcacy should be based
on the analysis of the neutralization of various toxic and enzymatic
activities (Gutierrez et al., 2013). In the early years of the 1980s, our
group at ICP initiated a long lasting effort to characterize the efﬁ-
cacy of ICP antivenoms (Gutierrez et al., 1981, 1985, 1996), and then
applied these methodologies to assess other antivenoms against
venoms from different regions of the world. Simple methods were
adapted or developed for the study of hemorrhagic, myotoxic,
dermonecrotic, edema-forming, coagulant, deﬁbrinogenating,
proteolytic, hyaluronidase, and PLA2 activities of venoms (see
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Regarding the neutralization of Bothrops sp snake venoms,
which inﬂict the highest number of snakebites in Latin America,
these studies have revealed a high extent of cross-neutralizing
ability of various antivenoms against several Bothrops sp venoms
(see for example Bogarín et al., 2000; Rojas et al., 2005; Segura
et al., 2010a). One of the most extensive studies performed in this
subject involved the participation of ten Latin American public in-
stitutions from Brazil, Argentina, Peru, Bolivia, Colombia, Panama
and Costa Rica, under the auspices of the Program CYTED (Ciencia y
Tecnología para el Desarrollo) (Segura et al., 2010a). In contrast to the
extensive cross-neutralization of Bothrops sp venoms by anti-
venoms, it was found that antivenoms produced using venoms of
the rattlesnake Crotalus simus from Central America are ineffective
in the neutralization of venoms of subspecies of Crotalus durissus
from South America, and viceversa (Saravia et al., 2002). This
methodological platform has been also used to investigate the
preclinical efﬁcacy of antivenoms used in sub-Saharan Africa
(Segura et al., 2010b; Sanchez et al., 2015), and in Papua New
Guinea (Vargas et al., 2011).
A signiﬁcant step forward in our understanding of antivenom's
ability to bind venom components came as a corollary of the de-
velopments in the ﬁeld of snake venom proteomics, i.e. ‘venomics’,
mostly through the work of the group of Juan J. Calvete, at the
Instituto de Biomedicina de Valencia (Spain) (Calvete et al., 2007).
Through an intensive collaboration with Calvete's group, scientists
at ICP have been able to characterize the proteomes of almost all
the venoms of Costa Rican snakes of the families Viperidae and
Elapidae (see Lomonte et al. (2014) for a review). Using the infor-
mation gathered from proteomics, the methodology known as
‘antivenomics’ was developed (Lomonte et al., 2008; Pla et al.,
2012). The so called ‘second generation’ antivenomics protocol
consists in performing afﬁnity chromatography, by passing snake
venoms through a Sepharose gel coupled with antivenomFig. 4. Scheme that summarizes the main events in the pathogenesis of local tissue dama
myotoxic phospholipases A2s (PLA2s) and zinc-dependent metalloproteinases, induce direct
degradation of extracellular matrix (ECM), and damage to lymphatic vessels and nerves. Suc
and edema. Resident cells in the tissue, such as macrophages and mast cells, become activate
damage or may provoke further pathology. In turn, inﬂammation is followed by reparativ
processes in the tissue, may result in functional regeneration or in scarring and tissue lossantibodies. In this way, venom components which are recognized,
or not recognized, by antivenom antibodies can be identiﬁed and
ascribed to the corresponding venom protein families (Pla et al.,
2012; Gutierrez et al., 2014). Using this approach, a detailed ac-
count of the immunoreactivity of the polyvalent (Viperidae) anti-
venom manufactured at ICP, when confronted with many snake
venoms, has been obtained (see Table 1 in Gutierrez et al., 2014).
The combination of neutralization tests and antivenomics now
provides a powerful methodological approach to analyze in detail
the preclinical efﬁcacy of antivenoms, and to make knowledge-
based decisions on how to improve antivenoms' neutralizing
coverage (Gutierrez et al., 2013).
5. Confronting snakebite envenoming from a broad
perspective: Central America and beyond
5.1. Improvements and innovation in antivenom manufacture
In addition to the described research, ICP has approached the
problem of snakebite envenoming by an integrated perspective
which includes the development, production and distribution of
antivenoms, and the creation of extension programs and advocacy
efforts at various levels. During its ﬁrst decade, ICP manufactured
the antivenoms that were needed in Costa Rica (Bola~nos and
Cerdas, 1980). On the basis of permanent innovation, the volume
of antivenom production steadily increased over the years, and ICP
started to cover the antivenom needs of other Central American
countries. These improvements have been possible due to the
commitment and dedication of the staff of the Industrial Division,
the Administrative Section, and the Directors of ICP. This institute
provides polyvalent (Viperidae) and anti-coral (Elapidae) anti-
venoms to Panama, Nicaragua, Honduras, El Salvador, Guatemala,
and Belize. More recently, ICP polyvalent antivenom has been
distributed to Ecuador, Peru, Colombia, Trinidad and Tobago, andge and inﬂammation induced by viperid snake venoms. Venom components, mostly
pathological effects upon injection in muscle tissue, such as myonecrosis, hemorrhage,
h widespread tissue pathology generates an inﬂammatory response which causes pain
d and contribute to the inﬂammatory scenario which might lead to resolution of tissue
e and regenerative responses which, depending on the balance between the various
. Modiﬁed from Gutierrez et al. (2007b).
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Initially, antivenoms were manufactured at ICP by a salting-out
procedure involving ammonium sulphate precipitation of plasma
proteins (Bola~nos and Cerdas, 1980). A signiﬁcant innovation was
introduced in the early 1990s by the use of caprylic acid precipi-
tation to separate non-immunoglobulin from immunoglobulin
proteins in equine plasma (Rojas et al., 1994), following previous
developments in Brazil (dos Santos et al., 1989). This protocol
generates antivenoms of high purity and yield, and of good physico-
chemical quality, thus becoming an alternative for antivenom
production; in fact, it is being currently used in laboratories of
several countries in Latin America and Asia. The creation of the
Technological Development Section (SEDETEC) at ICP provided the
impetus for the improvement of the technologies for antivenom
manufacture, and has generated new antivenoms for other regions.
Among other achievements, Guillermo Leon, Alvaro Segura, Mar-
iangela Vargas, María Herrera, and Mauren Villalta, at SEDETEC,
have adapted a new ‘two phase aqueous system’ method for equine
plasma fractionation (Vargas et al., 2015), and have introduced
improvements in aspects such as freeze-drying (Herrera et al.,
2014b) and stability (Segura et al., 2009) of antivenoms, in addi-
tion to investigating the mechanisms of adverse reactions to these
immunobiologicals (Leon et al., 2013), among other contributions.
5.2. A better understanding of snakebite epidemiology: providing
information for public health interventions
ICP has been interested in the study of the epidemiology of
snakebites in Costa Rica (Bola~nos, 1984; Arroyo et al., 1999; Sasa
and Vazquez, 2003). In addition, the use of Geographical Informa-
tion Systems (GIS) tools allowed a detailed analysis of the incidence
of snakebites in the various regions of the country, and showed that
the highest incidence occurs in the Central and South Paciﬁc re-
gions, in the Talamanca mountain range, in the Caribbean, and in
some counties of the Northern region (Hansson et al., 2013).
Therefore, although the general incidence of snakebites in the
country is around 14 per 100,000 population per year, drastic dif-
ferences in incidence occur at the county and district levels, some of
which have incidences higher than 100 per 100,000 population per
year (Hansson et al., 2013). The study also identiﬁed locations
where transportation to health facilities is more delayed. Another
study found that the incidence of snakebites is affected by weather
ﬂuctuations, and an association was observed between snakebites
and the cold and hot phases of El Ni~no Southern Oscillation (ENSO)
(Chaves et al., 2015). Moreover, it was described that snakebites
affect predominantly poor areas, thus reinforcing the concept that
this is a ‘disease of poverty’ (Harrison et al., 2009).
This epidemiological information is of high value for decision
makers at the public health system of the country, since it allows
the identiﬁcation of the most vulnerable regions that require spe-
cial attention. For instance, the deployment of antivenoms to pri-
mary health care centers, in addition to clinics and hospitals, can be
decided on the basis of this knowledge, in order to ensure the
availability of antivenoms where access to hospitals and clinics is
delayed. These developments underscore the relevance of estab-
lishing channels of communication and coordination between
research groups and public health authorities and practitioners.
5.3. Promoting prevention and appropriate management of
snakebite cases through extension programs
Since the onset of ICP, an extension programwas established for
conveying the basic concepts of prevention and early management
of snakebites in Costa Rica. It has been targeted especially at high
risk communities and groups, such as rural settings, includingthose of indigenous ethnic groups, agricultural workers, in-
stitutions whose staff has to travel to rural areas, and primary and
secondary education centers in areas of high incidence of snake-
bites. Awide array of teaching materials has been prepared, such as
manuals in both Spanish and languages of indigenous groups, as in
the case of Cabecar communities (Instituto Clodomiro Picado,
2009). These extension activities involve the participation of stu-
dents from the University of Costa Rica. Additionally, there is a
continuous education program on the treatment of snakebite
envenomings, directed to professionals in the medical ﬁeld, mostly
physicians and nurses. It includes teaching in university courses, as
well as seminars andworkshops in clinics and hospitals throughout
the country. The use of information and communication technol-
ogies has allowed the projection of these programs to rural hos-
pitals in Costa Rica and in other Central American countries. These
extension activities, over several decades, have improved the
knowledge of the general population on how to prevent snakebites
and what to do in the event of an accident. They have also
contributed to a better clinical management of snakebite enve-
nomings in health facilities.
5.4. Regional cooperation in Latin America
Latin America has had a long tradition in antivenom production,
starting with the pioneering work of Vital Brazil at Instituto
Butantan (Vital-Brazil, 1987). There are antivenom manufacturing
laboratories in Mexico, Costa Rica, Colombia, Venezuela, Ecuador,
Peru, Bolivia, Brazil, and Argentina (Gutierrez et al., 2007a). In the
last decade, regional integration has been promoted between
public laboratories devoted to the production and quality control of
antivenoms, and ICP has been directly involved in such projects.
These initiatives have been supported by the Pan American Health
Organization (PAHO), the Japanese International Cooperation
Agency (JICA), the Program CYTED (Ciencia y Tecnología para el
Desarrollo) and, more recently, the Organization of American States
(OAS). Activities performed include workshops, technical consul-
tations, training programs, and collaborative research projects (see
Gutierrez et al., 2007a, 2009). The involvement of Instituto Butan-
tan, among other institutions, has been essential, especially
through the leadership of Fan Hui Wen. These initiatives have
strengthened the regional capacity to produce and control anti-
venoms, and have consolidated a regional network of institutions
(Fig. 5).
Cooperative research projects between Latin American groups
have been developed in subjects as varied as biochemistry of snake
venoms, the mechanism of action of venoms and toxins, and pre-
clinical assessment and clinical evaluation of efﬁcacy and safety of
antivenoms. For instance, through a long standing collaboration
between ICP and Rafael Otero-Pati~no and colleagues, in Colombia, a
number of controlled, double-blind, randomized clinical trials have
been performed in that country using the polyvalent antivenom
produced at ICP (Otero et al., 1999, 2006; Otero-Pati~no et al., 2012).
5.5. Antivenom development for other regions of the world
The experience gained by ICP in technological development, and
in the manufacture and distribution of antivenoms in Latin Amer-
ica, paved the way, more than a decade ago, to new projects for the
development of novel antivenoms for other regions of the world.
Following a WHO workshop held in Potters Bar, London, in 2001
(Theakston et al., 2003), and in the light of a severe crisis in anti-
venom availability in sub-Saharan Africa (Theakston and Warrell,
2000), ICP joined a partnership with David G. Theakston and
Robert Harrison (Liverpool School of Tropical Medicine, UK), David
A. Warrell (University of Oxford, UK), Abdusalam Nasidi, Nandul
Fig. 6. ICP has participated in an international partnership aimed at generating anti-
venoms, improving snakebite envenoming treatment, and performing toxinological
research in Nigeria. This partnership, known as EchiTAb Study Group, has involved the
Federal Ministry of Health of Nigeria, the Liverpool School of Tropical Medicine (UK),
the University of Oxford (UK), and the company MicroPharm, together with ICP.
Among the various outcomes of this cooperation, two antivenoms [EchiTAb G
(Micropharm) and EchiTAb-Plus-ICP (ICP)] were developed and are regularly distrib-
uted to Nigeria. In addition, several research projects have contributed to a better
understanding of venoms and envenomings induced by snakes in this country.
Fig. 5. Network of public institutions for the production and quality control of anti-
venoms in Latin America. This network, supported by organizations such as CYTED
(Ciencia y Tecnología para el Desarrollo), OAS (Organization of American States), and
PAHO (Pan American Health Organization), as well as by the institutions themselves,
has promoted a dynamic partnership based on workshops, seminars, collaborative
research projects, training of staff, and technical consultations. Through these coop-
erative initiatives, the regional capacity to produce and control antivenoms has been
greatly improved in Latin America. ICP has played a leading role in these efforts.
BIRMEX: Laboratorios de Biologicos y Reactivos de Mexico; ICP: Instituto Clodomiro
Picado (Costa Rica); INVIMA: Instituto Nacional de Vigilancia de Medicamentos y
Alimentos (Colombia); INS: Instituto Nacional de Salud; U Panama: Universidad de
Panama; Biotecfar (Universidad Central de Venezuela); ENFARMA (Ecuador); U de San
Marcos: Universidad Nacional Mayor de San Marcos (Perú); INLASA: Instituto Nacional
de Laboratorios de Salud (Bolivia); FUNED: Fundaç~ao Ezequiel Dias (Brazil); Vital
Brazil: Instituto Vital Brazil (Brazil); INCQS: Instituto Nacional de Controle de Qual-
idade em Saúde (Brazil); Butantan: Instituto Butantan (Brazil); CPPI: Centro de
Produç~ao e Pesquisa de Imunobiologicos (Brazil); ANLIS: Administracion Nacional de
Laboratorios e Institutos de Salud (Argentina).
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Nigeria), and the company Micropharm (UK) (Fig. 6). This con-
sortium, known as EchiTAb Study Group, developed several ini-
tiatives aimed at improving antivenom availability for Nigeria. On
the basis of epidemiological, clinical, and immunological knowl-
edge, a new antivenomwas developed at ICP, using a mixture of the
venoms of Echis ocellatus, Bitis arietans and Naja nigricollis for im-
munization, and the puriﬁcation of antibodies from horse plasma
by the caprylic acid fractionation method (Gutierrez et al., 2005b).
This polyspeciﬁc antivenom, initially named ‘Pan-African anti-
venom’, and then known as ‘EchiTAb-Plus-ICP’, proved to be
effective at the preclinical level in the neutralization of the three
venoms used for immunization, as well as of other venoms of
medical relevance of the genera Echis, Bitis and Naja (Gutierrez
et al., 2005b; Segura et al., 2010b; Calvete et al., 2010). Then, this
antivenom was evaluated in a large clinical trial performed in
Nigeria, and showed satisfactory efﬁcacy and safety proﬁles in
envenomings by E. ocellatus (Abubakar et al., 2010). It has been
registered in various countries and is now regularly distributed to
sub-Saharan Africa.
Following this successful experience, a new partnership was
established between ICP and the universities of Melbourne
(Australia) and Papua New Guinea (PNG), with the participation of
David Williams, Kenneth Winkel, Simon Jensen, Owen Paiva and
Teatulohi Matainaho, together with the group of the Industrial
Division of ICP. The goal was to develop a potent and safe mono-
speciﬁc antivenom to be used in PNG for the treatment of enve-
nomings by the elapid snake Taipan (Oxyuranus scutellatus). In
parallel with the proteomic characterization of the venom (Herrera
et al., 2012), the new antivenom was shown to be effective at thepreclinical level (Vargas et al., 2011; Herrera et al., 2014a). It is now
being tested in a clinical trial in PNG and, depending on the results,
the long term purpose is to manufacture this antivenom at ICP for
distribution and use in PNG. The support of ICP's Directors, Gustavo
Rojas, Yamileth Angulo and Alberto Alape, has played a key role in
the success of these international initiatives.
Another project has started as a collaboration between ICP, the
University of Peradeniya (Sri Lanka), and the non-governmental
organization Animal Venom Research International (AVRI, USA),
with the participation of Indika Gawarammana, Daniel Keyler,
Kimberly McWhorter, Roy Malleappah, and Laki Wickremesinghe,
and the group of the Industrial Division of ICP. As a ﬁrst step, a new
polyspeciﬁc antivenom effective against the venoms of the most
important poisonous snakes of Sri Lanka will be developed.
Following a clinical trial, scheduled to start in 2016, the project aims
at implementing the transfer of the technology used at ICP for
antivenom production to Sri Lanka, with the support of the Tech-
nology Transfer Unit (PROINNOVA) of the University of Costa Rica,
in order to allow the local manufacture of the antivenom in this
Asian country (Keyler et al., 2013). If successful, this new model of
cooperation might be adapted, in the future, to other countries and
regions.5.6. Advocacy: raising global awareness of the impact of snakebite
envenoming
The commitment of ICP in the search for solutions to reduce the
impact of snakebite envenoming has also involved, together with
people of other institutions and countries, a number of advocacy
efforts. These include the participation in international workshops
and congresses, and in the preparation of the WHO Guidelines for
the Production, Control and Regulation of Snake Antivenom Immu-
noglobulins (WHO, 2010). Moreover, papers have been prepared to
promote awareness on the problem of snakebites (Gutierrez et al.,
2006, 2010, 2013), and contacts with national and international
health authorities have been established. ICP has been supportive
of the Global Snakebite Initiative (GSI), which is currently imple-
menting actions to confront the problem of snakebite envenoming
J.M. Gutierrez / Toxicon 109 (2016) 51e6260and its consequences (Williams et al., 2010; www.
snakebiteinitative.org).
6. Concluding remarks
This overview highlights part of what ICP has achieved, in Costa
Rica and in partnership with groups in many countries, for a better
understanding of venomous snakes, venoms, and their effects at
experimental and clinical levels. These efforts at the scientiﬁc realm
have been linked to the development of novel technological plat-
forms for the production and quality control of antivenoms, thus
contributing to the improvement of antivenom availability and
accessibility in Latin America, sub-Saharan Africa, and PNG.
Extension programs at national and regional levels have provided a
better understanding of the basic aspects of snakebite prevention
and management to communities and health professionals. Finally,
as a fourth component of this multifaceted strategy, ICP has
strengthened human resources in Costa Rica and elsewhere,
through teaching activities at graduate and undergraduate levels.
The involvement of students in the research projects of ICP has
been of paramount importance. The basic philosophy that has
guided this institutional project has been based on the search for
excellence and new challenges, a cooperative and collaborative
view of scientiﬁc work, an integrated approach to understanding
and solving a complex public health problem, and a vision of soli-
darity and compassion.
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